EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year book value per share growth
| Period | Value |
|---|---|
| Q4 2025 | 29.23% |
| Q3 2025 | -18.91% |
| Q2 2025 | -17.74% |
| Q1 2025 | -17.95% |
| Q4 2024 | 29.75% |
| Q3 2024 | -6.38% |
| Q2 2024 | -9.16% |
| Q1 2024 | -25.21% |
| Q4 2023 | 313.08% |
| Q3 2023 | 0.33% |
| Q2 2023 | -27.13% |
| Q1 2023 | -18.95% |
| Q4 2022 | -29.35% |
| Q3 2022 | -9.96% |
| Q2 2022 | -9.43% |
| Q1 2022 | -20.58% |
| Q4 2021 | 74.88% |
| Q3 2021 | -13.71% |
| Q2 2021 | -20.12% |
| Q1 2021 | 265.86% |
| Q4 2020 | 115.41% |
| Q3 2020 | 76.83% |
| Q2 2020 | -76.46% |
| Q1 2020 | 82.62% |
| Q4 2019 | -47.61% |
| Q3 2019 | -43.87% |
| Q2 2019 | 27.51% |
| Q1 2019 | -49.05% |
| Q4 2018 | -35.60% |
| Q3 2018 | 200.76% |
| Q2 2018 | 17.48% |
| Q1 2018 | -19.25% |
| Q4 2017 | -2.56% |
| Q3 2017 | -33.80% |
| Q2 2017 | -5.27% |
| Q1 2017 | -15.72% |
| Q4 2016 | 2.17% |
| Q3 2016 | -30.85% |
| Q2 2016 | -22.77% |
| Q1 2016 | 61.58% |